Etanercept Therapy for Nails Psoriasis Monitoring With Noninvasive Imaging
NCT ID: NCT05135312
Last Updated: 2022-01-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
10 participants
INTERVENTIONAL
2021-08-09
2022-08-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Observational Safety Study of Etanercept (Enbrel) for Treatment of Psoriasis
NCT00322439
The Immunological Basis for Treatment Resistance to Anti-TNF Treatments
NCT01971346
Utilization of Narrow Band Ultraviolet B (UVB) Light Therapy and Etanercept for the Treatment of Psoriasis
NCT00110981
Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet
NCT00585650
Canadian Assessment of Patient Outcomes and Effectiveness of Etanercept (Enbrel) in Psoriasis
NCT00332332
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
OCT is being studied as a way to better diagnosis psoriatic nail disease, monitor response to therapy, and identify changes even before they become apparent, potentially leading to earlier treatment or prevention of future psoriatic arthritis.
Study-related care and medication are provided at no cost, and reimbursement for reasonable local transportation may be available to qualified individuals.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Etanercept
50mg etanercept subcutaneously twice weekly for 3 months, followed by once weekly for another 3 months for a total duration of 6 months or 24 weeks.
Etanercept
TNF-alpha inhibitors improve nail psoriasis.
OCT
Optical Coherence Tomography is a noninvasive imaging device that can be used to monitor nail disease severity.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Etanercept
TNF-alpha inhibitors improve nail psoriasis.
OCT
Optical Coherence Tomography is a noninvasive imaging device that can be used to monitor nail disease severity.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Psoriasis affecting the fingernails
Exclusion Criteria
* Active infection
* Rheumatoid arthritis
* Any personal or family history of any neurologic demyelinating disease
* Receipt of investigational drugs or "biologics" within 4 weeks of the screening visit
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Amgen
INDUSTRY
OptiSkin Medical
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Orit Markowitz MD
Chief Medical Ofiicer
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Orit Markowitz, MD
Role: PRINCIPAL_INVESTIGATOR
OptiSkin Medical
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
OptiSkin Medical
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OPTI-004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.